RETRACTION NOTE

Retraction Note to: A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients

Jun Yao¹ · Jian-yao Wang² · Yi Liu³ · Bin Wang² · Ying-xue Li¹ · Ru Zhang¹ · Li-Sheng Wang¹ · Lei Liu²

Published online: 21 July 2015
© Springer Science+Business Media New York 2015

Retraction Note to: Med Oncol (2014) 31:251
DOI 10.1007/s12032-014-0251-x

This article has been retracted by the authors because the authors discovered statistical errors which need further validation.

The online version of the original article can be found under doi:[10.1007/s12032-014-0251-x](https://doi.org/10.1007/s12032-014-0251-x).

✉ Li-Sheng Wang
wangls168@163.com

✉ Lei Liu
liulei3322@yahoo.com.cn

¹ Department of Gastroenterology, Shenzhen Municipal People's Hospital, Jinan University of Medical Sciences, 1017 East Gate Road, Shenzhen 518020, Guangdong Province, China

² Department of General Surgery, Shenzhen Children's Hospital, Shenzhen 518026, Guangdong Province, China

³ Translational Medicine Center, Laboratory of Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China